Compare LGIH & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | PRCT |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2013 | 2021 |
| Metric | LGIH | PRCT |
|---|---|---|
| Price | $42.40 | $19.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 340.8K | ★ 1.3M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,705,504,000.00 | $308,054,000.00 |
| Revenue This Year | $6.07 | $28.32 |
| Revenue Next Year | $11.62 | $20.48 |
| P/E Ratio | $34.07 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $33.55 | $16.67 |
| 52 Week High | $66.25 | $38.11 |
| Indicator | LGIH | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 57.00 |
| Support Level | $39.35 | $19.87 |
| Resistance Level | $51.77 | $22.88 |
| Average True Range (ATR) | 2.26 | 1.03 |
| MACD | 0.06 | 0.29 |
| Stochastic Oscillator | 42.96 | 93.10 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.